
In her second lecture Nataliia Vladykina turns to the complications of stimulation — "every reproductive specialist's bogeyman." Her thesis: complications happen to everyone, they are rare, but to avoid even the rare ones you must speak about them openly.
She begins with the non-standard response to stimulation — the most frequent topic of questions. Three sources of such a situation: iatrogenic influence (long use of combined pills, agonists, treating endometriosis before stimulation), biological ageing and a genetic factor.
A separate point is the difference between a polymorphism and a mutation: a mutation practically switches off the possibility of stimulation, whereas polymorphisms only alter the response — some suppress it, others make it hyper. Hence an unexpected hypo- or hyper-response in a seemingly "predictable" patient; unified protocols do not work here.
Empty follicle syndrome is more often false: the patient did not administer the trigger correctly (wrong day, agonist not reconstituted). Hence the importance of trigger control: an ovulation or pregnancy test the next day, video and messages. The true syndrome is linked to an individual response to the trigger — re-aspiration at 40-42 hours instead of 36.
Resistant follicle syndrome — when a patient was mistakenly taken for stimulation: normal/raised AMH and antral follicles with high FSH and LH. The gold standard is genotyping: for some mutations only IVM is possible, for others moderate stimulation.
Ovarian torsion is a rare but unpleasant complication; predisposing factors are rapid follicle growth and multifollicular ovaries. A key point: Doppler is wrong up to 60% of the time (arterial flow persists in torsion), so a diagnosis by "flow present" is unreliable.
Spontaneous ovarian rupture differs in presentation: sharp pain and sudden loss of consciousness (unlike torsion, where consciousness is preserved). Management depends on haemodynamics: stable — observation, unstable — infusion, theatre. A personal case of combined torsion and rupture is presented, where the ovary was saved and 28 cells and a pregnancy obtained the next day.
The central complication is ovarian hyperstimulation syndrome (OHSS). After the era of agonist triggers it nearly disappeared, but the "fashion" for the dual trigger brought the OHSS picture back: even a little hCG launches the cascade. OHSS is not simply a response to stimulation but a pathogenetic process, seen even outside IVF protocols.
OHSS prevention: identifying high-risk patients (phenotype, multifollicular ovaries, history), an agonist protocol, metformin in PCOS, an agonist trigger, cabergoline (reduces severity but not incidence), freeze-all and transfer in a later cycle. What does not work: low-dose hCG, letrozole, aspirin, albumin and starches.
The overall message: complications will always occur, they should not be feared but approached with judgement — anticipate the risk, react in time and explain everything to the patient at every stage. Then the work stays reasonably safe even in rare critical situations.
Most stimulation complications are predictable. How to assess the risk of ovarian hyperstimulation syndrome, when an agonist trigger and freeze-all are the rescue, how to choose the final maturation trigger, and which mistakes cost a cycle — a practical review of prevention.
Patients arrive at the clinic already having consulted ChatGPT, and regulators are reviewing the first AI ‘doctors’. What in artificial intelligence already works in reproductive medicine — from assistant avatars to embryo assessment and stimulation personalisation? A live discussion on three levels — strategy, service and clinic — with practical cases and a panel Q&A.


A Sona-Pharm grant award for specialists in infertility treatment. Applications open on 1 February 2027. Ceremony — July 2027, Stockholm, during the ESHRE meeting.

Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.
Audio: UASubtitles: UA32 min
